NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biora Therapeutics, Inc. ("Biora" or the "Company") (NASDAQ:BIOR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Biora and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On October 23, 2023, Biora announced that the Company would need additional time to submit its Investigational New Drug application ("IND") for its drug/device combination BT-600 for ...